Key players in GLP-1 Receptor Agonists
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 |  Novo Nordisk A/S |
novo.com (opens in a new tab) | 495 reports |
| 2 |  Eli Lilly and Company |
lilly.com (opens in a new tab) | 1,056 reports |
| 3 |  AstraZeneca |
astrazeneca.com (opens in a new tab) | 957 reports |
| 4 |  Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 5 |  Amgen Inc. |
amgen.com (opens in a new tab) | 693 reports |
| 6 |  Pfizer Inc. |
pfizer.com (opens in a new tab) | 2,310 reports |
Also active in GLP-1 Receptor Agonists
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
| Orbicular | |
| Biocon | |
 Hikma Pharmaceuticals PLC |
|
| Emerge Bioscience | |
 Teva Pharmaceutical |
|
| Lupin Ltd |
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
GLP-1 Receptor Agonists reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full GLP-1 Receptor Agonists report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.